EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy

Youngjoo Lee, Sukyung Song, Suah Yang, Jinseong Kim, Yujeong Moon, Nayeon Shim, Hong Yeol Yoon, Sehoon Kim, Man Kyu Shim, Kwangmeyung Kim

Acta Pharmaceutica Sinica B · 2024-03 · 14 (3) · 1428-1440

DOI: 10.1016/j.apsb.2023.09.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2024-03. Verfasst von Youngjoo Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning, Korea Institute of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) therapy targeting PD-L1 via monoclonal antibody (mAb) has shown extensive clinical benefits in the diverse types of advanced malignancies. However, most patients are completely refractory to ICB therapy owing to the PD-L1 recycling mechanism. Herein, we propose photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes (immune checkpoint blockade liposomes; ICB-LPs) to promote PD-L1 multivalent binding for inducing lysosomal degradation of PD-L1 in tumor cells. The ICB-LPs are prepared by formulation of DC8,9PC with photo-polymerized diacetylenic moiety, 1,2-dipalmitoylphosphatidylcholine (DPPC) and anti-PD-L1 peptide (D-form NYSKPTDRQYHF)-conjugated DSPE-PEG2k (anti-PD-L1-DSPE-PEG2k) in a molar ratio of 45:45:10, followed by cross-linking of liposomal bilayer upon UV irradiation. The 10 mol% anti-PD-L1-DSPE-PEG2k incorporated ICB-LPs have a nano-sized lipid bilayer structure with an average diameter of 137.7 ± 1.04 nm, showing a high stability in serum condition. Importantly, the ICB-LPs efficiently promote the multivalent binding with PD-L1 on the tumor cell membrane, which are endocytosed with aim to deliver PD-L1 to the lysosomes, wherein the durable PD-L1 degradation is observed for 72 h, in contrast to anti PD-L1 mAbs showing the rapid PD-L1 recycling within 9 h. The in vitro co-culture experiments with CD8+ T cells show that ICB-LPs effectively enhance the T cell-mediated antitumor immune responses against tumor cells by blocking the PD-L1/PD-1 axis. When ICB-LPs are intravenously injected into colon tumor-bearing mice, they efficiently accumulate within the targeted tumor tissues via both passive and active tumor targeting, inducing a potent T cell-mediated antitumor immune response by effective and durable PD-L1 degradation. Collectively, this study demonstrates the superior antitumor efficacy of crosslinked and anti-PD-L1 peptide incorporated liposome formulation that promotes PD-L1 multivalent binding for trafficking of PD-L1 toward the lysosomes instead of the recycling endosomes.

Schlagwörter

Stichwörter der Autor:innen

Anti-PD-L1 peptideCancer immunotherapyCrosslinked lipid nanoparticlesImmune checkpoint blockadeLysosomal PD-L1 degradationPD-L1 multivalent bindingPEGylated liposomeTumor-targeting

Autor:innen und Institutionen

  • KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea.
  • Medicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
  • College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
  • Department of Bioengineering, Korea University, Seoul 02841, Republic of Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science, ICT and Future Planning
  • Korea Institute of Science and Technology

Zitieren

APA

Lee, Y., Song, S., Yang, S., Kim, J., Moon, Y., Shim, N., Yoon, H. Y., Kim, S., Shim, M. K., & Kim, K. (2024). Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy. Acta Pharmaceutica Sinica B, 14(3), 1428-1440. https://doi.org/10.1016/j.apsb.2023.09.007

Vancouver

Lee Y, Song S, Yang S, Kim J, Moon Y, Shim N, et al. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy. Acta Pharmaceutica Sinica B. 2024;14(3):1428-1440. doi:10.1016/j.apsb.2023.09.007

BibTeX
@article{Lee2024,
  author = {Lee, Youngjoo and Song, Sukyung and Yang, Suah and Kim, Jinseong and Moon, Yujeong and Shim, Nayeon and Yoon, Hong Yeol and Kim, Sehoon and Shim, Man Kyu and Kim, Kwangmeyung},
  title = {Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2024},
  volume = {14},
  number = {3},
  pages = {1428--1440},
  doi = {10.1016/j.apsb.2023.09.007}
}
Kostenlos starten →